OncoLink at ASCO 2001: Tuesday, May 15 | Oncolink

Oncolink Features

Find My Cancer Drug

American Cancer Society Award Winner Sidney Winawer, MD, Discusses the Progress and Promise of Colorectal Cancer Screening "The best screening test is the screening test that gets done." That was the central point repeatedly made by Sidney Winawer, MD, Chief of Gastroenterology at Memorial Sloan Kettering Cancer Center, as he sketched out a twenty-five year...
Bone Mineral Density In Premenopausal Patients In A Randomized Trial Of Adjuvant Endocrine Therapy (ZIPP-TRIAL) Presenter: Asgerdur Sverrisdóttir Affiliation: University Hospital, Stockholm, Sweden Background: There is evidence that ovarian ablation can improve survival in pre-menopausal patients with early-stage breast cancer. However, there is ...
Clinical Significance Of Axillary Micrometastases In Breast Cancer: How Small Is Too Small? Presenter: Nora M Hansen Affiliation: John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA Background: Lymph node metastases are the most significant prognostic indicator for patients with breast cancer. a. 15-20% LN ?...
Comparison Of Lumpectomy Plus Tamoxifen With And Without Radiotherapy (RT) In Women 70 Years Of Age Or Older Who Have Clinical Stage I, Estrogen Receptor Positive (ER+) Breast Carcinoma Presenter: Kevin S. Hughes Affiliation: Massachusetts General Hospital Background: No survival impact of RT from previous studies. Tumor in this group of pts grow slowly, therefore, less time at risk. This study is designed to assess, in this...
Effect Of Raloxifene After Tamoxifen On Breast And Endometrial Cancer Growth Presenter: Ruth M. O'Regan Affiliation: Northwestern University, Chicago, IL Background: After the completion of 5 years of tamoxifen therapy, breast cancer patients are still at risk for osteoporosis and breast cancer recurrence. Raloxifene...
Incidence And Prognostic Impact Of Amenorrhea During Adjuvant Therapy In High Risk Premenopausal Breast Cancer Patients: Analysis Of A National Cancer Institute Of Canada Clinical Trials Group (NCIC CTG) Phase III Study Presenter: W. Parulekar Affiliation: Kingston, ON, Canada Background: One of the consequences of adjuvant therapy for breast cancer is drug-induced amenorrhea. The incidence and prognostic impact of drug induced amenorrhea (DIA) during...
Overall Survival After Cyclophosphamide, Adriamycin, 5-FU, And Tamoxifen (CAFT) Is Superior To T Alone In Postmenopausal, Receptor (+), Node (+) Breast Cancer: New Findings From Phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100) Presenter: Kathy Albain Affiliation: Loyola Univ. Med. Center, Maywood, IL Background: The treatment of older women with breast cancer presents many unique treatment issues. One such issue is the use of anthracyclines to treat older patients...
Preliminary Results Of A Randomized Study Of Tamoxifen +/- Breast Radiation In T1/2 N0 Disease In Women Over 50 Years Of Age Presenter: Anthony Fyles Affiliation: Princess Margaret Hospital, Toronto, ON, Canada Background: Breast radiation (RT) shows definitive reduction in local relapses, however, with moderal toxicity and without a survival benefit. In Tamoxifen...
Preventing Chemotherapy-associated Amenorrhea (CRA) With Leuprolide In Young Women With Early-stage Breast Cancer Presenter: Kevin R. Fox Affiliation: University of Pennsylvania Cancer Center, Philadelphia, PA Background: Premature amenorrhea is often associated with adjuvant chemotherapy treatment for breast cancer. The rate of amenorrhea varies to 10 to...
Radiation Therapy Oncology Group (RTOG) 95-14; a phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall: a preliminary report Presenter: W.G.Kraybill Affiliation: RTOG Background: Radiation therapy plays a central role in the management of many soft tissue sarcomas and allows for a substantial reduction in the extent of surgical resection. The addition of ...
Response to neoadjuvant thermochemotherapy as significant prognosticator for long-term survival of patients with retroperitoneal or visceral high-risk soft-tissue sarcoma Presenter: C.M.Wendtner Affiliation: Ludwig-Maximilian-University Background: The clinical application of hyperthermia with increase of tissue temperatures (range 40-44 degrees C) has been integrated in multimodal anti- cancer strategies. The...
Second Malignant Neoplasms (SMN) In Children Treated For Rhabdomyosarcoma: A Report From The Intergroup Rhabdomyosarcoma Studies (IRS) I-IV Presenter: Sheri L. Spunt Affiliation: Children's Oncology Group Soft Tissue Sarcoma Committee, Arcadia, CA Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of the childhood (5%). Multimodality therapy can provide cure...
Therapy-related Myelodysplasia (T-MDS/T-AML) Following Treatment Of Children With Osteosarcoma Presenter: Smita Bhatia Affiliation: City of Hope Comprehensive Cancer Center, Duarte, CA Background: T-MDS/T-AML is known to be associated with anti-neoplastic treatment. With alkylating agents, T-MDS/T-AML is associated with deletion of...